Abstract: A method is disclosed of treating a patient having viral pneumonia secondary to COVID-19 using IV infusion of mesenchymal stem cells in patients receiving COVID-19 vaccination. The vaccine may be Pfizer, Moderna, Johnson & Johnson or Astra Zenica COVID-19 vaccine, for example and the patient may be treated with an mRNA-based vaccine followed by IV-infusion of 100 million MSCs. MSCs can be derived from patients who have been exposed to the COVID-19 virus. Moreover, the MSCs may be derived from the umbilical cord of a donor.

Abstract: The present invention provides materials and methods to reprogram adult stem cells without transfection of foreign genes through the employment of appropriate environmental factors. Cells made via these processes are also provided. Methods to use the pluripotent cells are also provided.

Abstract: The present invention teaches a new method of stem cell generation involving the establishment of a mesenchymal cell culture, induction of epithelial marker expression and isolation and cloning of the cells expressing epithelial markers and expansion of these cell lines. Further processes are described for a two-step method to induce the differentiation of terminally differentiated cell types such as insulin-producing beta cells of the human pancreas gland. The invention indicates that mesenchymal to epithelial transition may be an important component in the development, renewal and regeneration of animal organ systems and provides a reliable method for in-vitro generation of adult stem cells and terminally differentiated cell types for various uses in medical research and cell therapy of disease.

Abstract: The present diagnostic test kit and methods of diagnosis and treatment of Helicobacter spp. associated infections provides accurate diagnosis and treatment for Helicobacter spp. related infections and diseases. The method of diagnosis includes analyzing a tissue specimen from a patient diagnosed with a disease. The tissue specimen can be a tumor cell related to the diagnosed disease of the patient. The tissue specimen is analyzed for the presence of Helicobacter spp. DNA or its components. One such analysis includes fluorescent in-situ hybridization (FISH). Once the presence of Helicobacter spp. DNA and/or its components is detected, the patient may be treated with a host of treatments including antibiotic therapy, molecular signal therapy, vaccination, interference with receptor systems mediating Helicobacter spp. invasion into tissues, and use of small-interfering RNA sequences to specifically block virulence or replication of Helicobacter spp.